HVB MINI FUTURE BEAR - ASTRAZENECA | Real-time BOERSE MUENCHEN 14:45:30 23/05/2024 BST | ||
| 2.39 EUR | -4.40% |
|
| Current month | -11.35% | ||
| 1 month | -30.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 2.39 | -4.40% |
| 22/05/24 | 2.5 | +3.73% |
| 21/05/24 | 2.41 | -13.31% |
| 20/05/24 | 2.78 | +1.83% |
| 17/05/24 | 2.73 | +1.87% |
Real-time BOERSE MUENCHEN
Last update May 23, 2024 at 02:45 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HC69S9 |
| ISIN | DE000HC69S98 |
| Date issued | 25/04/2023 |
| Strike | 14,425 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.73 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.95 € |
|---|---|
| Lowest since issue | 2.34 € |
| Spread | 0.01 € |
| Spread % | 0.42% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.3
USD
Average target price
169.7
USD
Spread / Average Target
+7.87%
- Stock Market
- Certificates
- Certificat
